Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion
Rhea-AI Summary
Tenon Medical (NASDAQ:TNON) announced a strategic expansion of its intellectual property portfolio on February 18, 2026, following USPTO Notices of Allowance for multiple patent applications expected to issue in 2026. The company reported a portfolio of 29 issued U.S. patents, 9 international patents, and 31 pending applications.
Tenon also cited its recent asset acquisition of SIVantage's SImmetry and SImmetry+ systems, supported by 16 issued U.S. patents, which the company says complements the Catamaran platform and strengthens protection for its sacro-pelvic fusion technologies.
Positive
- 29 issued U.S. patents strengthening domestic protection
- 9 issued international patents expanding global IP coverage
- 31 pending applications indicating continued pipeline expansion
- Acquisition of SImmetry systems backed by 16 U.S. patents
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TNON gained 8.22% while Argus momentum peers showed mixed moves: SSKN -20.96%, PAVM -2.63%, and BMRA +7.62%. Sector data notes 2 peers moving down, suggesting broader pressure, but TNON’s upside reaction diverges from those declines.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings date set | Positive | -2.3% | Set Q4/FY 2025 earnings date and reaffirmed strong revenue growth ranges. |
| Jan 28 | Preliminary revenues | Positive | -1.6% | Released preliminary Q4 and FY 2025 revenues with strong year-over-year growth. |
| Dec 04 | Product launch cases | Positive | +0.0% | Announced initial clinical cases with new SImmetry+ SI Joint Fusion System. |
| Nov 14 | PIPE financing | Neutral | +0.0% | Closed $2.85M at-the-market PIPE financing with new shares and warrants. |
| Nov 13 | Q3 2025 earnings | Neutral | -8.5% | Reported Q3 2025 growth, higher gross margin, and ongoing net loss with cash update. |
Recent fundamentally positive updates (revenue growth, product launches) often saw flat-to-negative price reactions, while today’s IP expansion aligns with a positive move.
Over the last few months, Tenon reported strong revenue growth, with Q3 2025 revenue of $1.2M and ~32% year-over-year growth, and projected Q4 2025 revenue of $1.45–$1.48M (~90% YoY) and FY 2025 revenue of $3.91–$3.94M. It completed the SiVantage asset acquisition, launched the SImmetry+ system, and raised $2.85M via an at-the-market PIPE. Those milestones sometimes met with negative or flat reactions. Today’s patent-focused news extends this strategy by reinforcing protection around the Catamaran and SImmetry platforms.
Market Pulse Summary
This announcement emphasized a significant expansion of Tenon’s intellectual property, including new USPTO allowances and a portfolio totaling 29 issued U.S. patents, 9 issued international patents, and 31 pending applications. It builds on prior milestones such as the SiVantage asset acquisition and SImmetry+ rollout, reinforcing protection around the sacroiliac fusion platform. Investors may track how this IP depth supports procedure adoption, revenue growth, and future financing flexibility alongside upcoming Q4/FY 2025 earnings details.
Key Terms
united states patent and trademark office regulatory
sacro-pelvic disorders medical
AI-generated analysis. Not financial advice.
Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy
LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen the Company's growing patent portfolio and build upon the (10) ten patents issued in 2025, including (5) five issued by the USPTO and (5) five issued internationally.
These patents strengthen protection around key systems and methods underlying the Company's Catamaran® SI Joint Fusion System and further reinforce Tenon's commitment to innovation in sacro-pelvic fusion. In addition, the Company anticipates the issuance of additional patent applications in 2026, which would further expand and enhance its growing intellectual property portfolio.
The Company continues to diversify its intellectual property through the recent strategic asset acquisition of SIVantage®'s SImmetry® and SImmetry®+ lateral SI joint fusion systems. Supported by (16) sixteen issued U.S. patents, the SImmetry and SImmetry+ sacroiliac joint fusion systems bring a well-established clinical foundation and a differentiated fusion approach that complements and expands Tenon's existing Catamaran platform.
Backed by a robust innovation pipeline designed to drive continued procedure adoption and revenue growth, the Company expects to further expand and strengthen the intellectual property protection surrounding its Catamaran and SImmetry+ SI Joint implant systems. The portfolio currently includes (29) twenty-nine issued U.S. patents and (9) nine issued international patents, along with (31) thirty-one pending U.S. and foreign patent applications.
"Our intellectual property strategy is foundational to Tenon's long-term growth," said Richard Ginn, Chief Operating Officer and Co-Founder of Tenon Medical. "Building and protecting a strong global patent portfolio ensures that the innovation we are pioneering - and delivering to physicians and their patients - remains differentiated and defensible in a competitive market. Efforts such as these further solidify our patent position, safeguard our technology platform, strengthen our competitive standing within the industry, and underscore our commitment to advancing less invasive sacroiliac joint solutions. Protecting our innovation today enables us to invest confidently in the next generation of technologies that will bring value to our shareholders, but more importantly continue to redefine care for patients suffering from sacro-pelvic disorders as well."
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Safe Harbor
This press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain, and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of numerous factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
What intellectual property update did Tenon Medical (TNON) announce on February 18, 2026?
How does Tenon describe the impact of the SImmetry acquisition on TNON's patent portfolio?
What patent protections support Tenon's Catamaran SI Joint Fusion System (TNON)?
How many pending patent applications did Tenon report for its sacro-pelvic technologies?
Will the newly allowed patents for TNON issue in 2026 and what is their expected role?
How does Tenon link its IP strategy to shareholder value and clinical adoption (TNON)?
